Hemab Therapeutics Holdings, Inc. (COAG) stock
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.06+0.01 (+0.01%)
Close on Nov 17, 2026Market cap $1.82BP/E –Yield –
Hemab Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
No enterprise value figures for Hemab Therapeutics
Hemab Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?